-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $60

Benzinga·08/31/2026 10:23:29
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Buy rating and announces Price Target of $60.